O	0	1	M	M	NN	B-NP
O	1	2	-	-	HYPH	I-NP
O	2	5	CSF	CSF	NN	I-NP
O	6	13	signals	signal	NNS	I-NP
O	14	21	through	through	IN	B-PP
O	22	25	the	the	DT	B-NP
O	26	30	MAPK	MAPK	NN	I-NP
O	30	31	/	/	SYM	B-NP
O	31	34	ERK	ERK	NN	I-NP
O	35	42	pathway	pathway	NN	I-NP
O	43	46	via	via	IN	B-PP
O	47	50	Sp1	Sp1	NN	B-NP
O	51	53	to	to	TO	B-VP
O	54	60	induce	induce	VB	I-VP
O	61	65	VEGF	VEGF	NN	B-NP
O	66	76	production	production	NN	I-NP
O	77	80	and	and	CC	O
O	81	88	induces	induce	VBZ	B-VP
O	89	101	angiogenesis	angiogenesis	NN	B-NP
O	102	104	in	in	FW	B-ADVP
O	105	109	vivo	vivo	FW	I-ADVP
O	109	110	.	.	.	O

O	111	121	BACKGROUND	BACKGROUND	NN	B-NP
O	121	122	:	:	:	O
O	123	124	M	M	NN	B-NP
O	124	125	-	-	HYPH	O
O	125	128	CSF	CSF	NN	B-NP
O	129	137	recruits	recruit	VBZ	B-VP
B-Cell	138	149	mononuclear	mononuclear	JJ	B-NP
I-Cell	150	160	phagocytes	phagocyte	NNS	I-NP
O	161	166	which	which	WDT	B-NP
O	167	175	regulate	regulate	VBP	B-VP
O	176	185	processes	process	NNS	B-NP
O	186	190	such	such	JJ	B-PP
O	191	193	as	as	IN	I-PP
O	194	206	angiogenesis	angiogenesis	NN	B-NP
O	207	210	and	and	CC	I-NP
B-Cancer	211	221	metastases	metastasis	NNS	I-NP
O	222	224	in	in	IN	B-PP
B-Cancer	225	231	tumors	tumor	NNS	B-NP
O	231	232	.	.	.	O

O	233	237	VEGF	VEGF	NN	B-NP
O	238	240	is	be	VBZ	B-VP
O	241	242	a	a	DT	B-NP
O	243	249	potent	potent	JJ	I-NP
O	250	259	activator	activator	NN	I-NP
O	260	262	of	of	IN	B-PP
O	263	275	angiogenesis	angiogenesis	NN	B-NP
O	276	278	as	as	IN	B-SBAR
O	279	281	it	it	PRP	B-NP
O	282	290	promotes	promote	VBZ	B-VP
B-Cell	291	302	endothelial	endothelial	JJ	B-NP
I-Cell	303	307	cell	cell	NN	I-NP
O	308	321	proliferation	proliferation	NN	I-NP
O	322	325	and	and	CC	O
O	326	329	new	new	JJ	B-NP
B-Multi-tissue_structure	330	335	blood	blood	NN	I-NP
I-Multi-tissue_structure	336	342	vessel	vessel	NN	I-NP
O	343	352	formation	formation	NN	I-NP
O	352	353	.	.	.	O

O	354	364	Previously	Previously	RB	B-ADVP
O	364	365	,	,	,	O
O	366	368	we	we	PRP	B-NP
O	369	377	reported	report	VBD	B-VP
O	378	382	that	that	IN	B-SBAR
O	383	385	in	in	FW	B-NP
O	386	391	vitro	vitro	FW	I-NP
O	392	393	M	M	NN	I-NP
O	393	394	-	-	HYPH	B-NP
O	394	397	CSF	CSF	NN	I-NP
O	398	405	induces	induce	VBZ	B-VP
O	406	409	the	the	DT	B-NP
O	410	420	expression	expression	NN	I-NP
O	421	423	of	of	IN	B-PP
O	424	436	biologically	biologically	RB	B-NP
O	436	437	-	-	HYPH	I-NP
O	437	443	active	active	JJ	I-NP
O	444	448	VEGF	VEGF	NN	I-NP
O	449	453	from	from	IN	B-PP
O	454	459	human	human	JJ	B-NP
B-Cell	460	469	monocytes	monocyte	NNS	I-NP
O	469	470	.	.	.	O

O	471	482	METHODOLOGY	METHODOLOGY	NN	B-NP
O	483	486	AND	AND	CC	I-NP
O	487	494	RESULTS	RESULTS	NNS	I-NP
O	494	495	:	:	:	O
O	496	498	In	In	IN	B-PP
O	499	503	this	this	DT	B-NP
O	504	509	study	study	NN	I-NP
O	509	510	,	,	,	O
O	511	513	we	we	PRP	B-NP
O	514	525	demonstrate	demonstrate	VBP	B-VP
O	526	529	the	the	DT	B-NP
O	530	539	molecular	molecular	JJ	I-NP
O	540	549	mechanism	mechanism	NN	I-NP
O	550	552	of	of	IN	B-PP
O	553	554	M	M	NN	B-NP
O	554	555	-	-	HYPH	B-NP
O	555	558	CSF	CSF	NN	I-NP
O	558	559	-	-	HYPH	B-NP
O	559	566	induced	induce	VBN	I-NP
O	567	571	VEGF	VEGF	NN	I-NP
O	572	582	production	production	NN	I-NP
O	582	583	.	.	.	O

O	584	589	Using	Use	VBG	B-VP
O	590	591	a	a	DT	B-NP
O	592	601	construct	construct	NN	I-NP
O	602	612	containing	contain	VBG	B-VP
O	613	616	the	the	DT	B-NP
O	617	621	VEGF	VEGF	NN	I-NP
O	622	630	promoter	promoter	NN	I-NP
O	631	637	linked	link	VBN	B-VP
O	638	640	to	to	TO	B-PP
O	641	642	a	a	DT	B-NP
O	643	653	luciferase	luciferase	NN	I-NP
O	654	662	reporter	reporter	NN	I-NP
O	662	663	,	,	,	O
O	664	666	we	we	PRP	B-NP
O	667	672	found	find	VBD	B-VP
O	673	677	that	that	IN	B-SBAR
O	678	679	a	a	DT	B-NP
O	680	688	mutation	mutation	NN	I-NP
O	689	697	reducing	reduce	VBG	B-VP
O	698	701	HIF	HIF	NN	B-NP
O	702	709	binding	binding	NN	I-NP
O	710	712	to	to	TO	B-PP
O	713	716	the	the	DT	B-NP
O	717	721	VEGF	VEGF	NN	I-NP
O	722	730	promoter	promoter	NN	I-NP
O	731	734	had	have	VBD	B-VP
O	735	737	no	no	DT	B-NP
O	738	749	significant	significant	JJ	I-NP
O	750	756	effect	effect	NN	I-NP
O	757	759	on	on	IN	B-PP
O	760	770	luciferase	luciferase	NN	B-NP
O	771	781	production	production	NN	I-NP
O	782	789	induced	induce	VBN	B-VP
O	790	792	by	by	IN	B-PP
O	793	794	M	M	NN	B-NP
O	794	795	-	-	HYPH	I-NP
O	795	798	CSF	CSF	NN	I-NP
O	799	810	stimulation	stimulation	NN	I-NP
O	810	811	.	.	.	O

O	812	819	Further	Further	JJ	B-NP
O	820	828	analysis	analysis	NN	I-NP
O	829	837	revealed	reveal	VBD	B-VP
O	838	842	that	that	IN	B-SBAR
O	843	844	M	M	NN	B-NP
O	844	845	-	-	HYPH	B-NP
O	845	848	CSF	CSF	NN	I-NP
O	849	856	induced	induce	VBD	B-VP
O	857	861	VEGF	VEGF	NN	B-NP
O	862	869	through	through	IN	B-PP
O	870	873	the	the	DT	B-NP
O	874	878	MAPK	MAPK	NN	I-NP
O	878	879	/	/	SYM	B-NP
O	879	882	ERK	ERK	NN	I-NP
O	883	892	signaling	signaling	NN	I-NP
O	893	900	pathway	pathway	NN	I-NP
O	901	904	via	via	IN	B-PP
O	905	908	the	the	DT	B-NP
O	909	922	transcription	transcription	NN	I-NP
O	923	929	factor	factor	NN	I-NP
O	929	930	,	,	,	O
O	931	934	Sp1	Sp1	NN	B-NP
O	934	935	.	.	.	O

O	936	940	Thus	Thus	RB	B-ADVP
O	940	941	,	,	,	O
O	942	952	inhibition	inhibition	NN	B-NP
O	953	955	of	of	IN	B-PP
O	956	962	either	either	CC	O
O	963	966	ERK	ERK	NN	B-NP
O	967	969	or	or	CC	I-NP
O	970	973	Sp1	Sp1	NN	I-NP
O	974	984	suppressed	suppress	VBD	B-VP
O	985	986	M	M	NN	B-NP
O	986	987	-	-	HYPH	B-NP
O	987	990	CSF	CSF	NN	I-NP
O	990	991	-	-	HYPH	B-NP
O	991	998	induced	induce	VBN	I-NP
O	999	1003	VEGF	VEGF	NN	I-NP
O	1004	1006	at	at	IN	B-PP
O	1007	1010	the	the	DT	B-NP
O	1011	1015	mRNA	mRNA	NN	I-NP
O	1016	1019	and	and	CC	I-NP
O	1020	1027	protein	protein	NN	I-NP
O	1028	1033	level	level	NN	I-NP
O	1033	1034	.	.	.	O

O	1035	1036	M	M	NN	B-NP
O	1036	1037	-	-	HYPH	I-NP
O	1037	1040	CSF	CSF	NN	I-NP
O	1041	1045	also	also	RB	B-ADVP
O	1046	1053	induced	induce	VBD	B-VP
O	1054	1057	the	the	DT	B-NP
B-Cellular_component	1058	1065	nuclear	nuclear	JJ	I-NP
O	1066	1078	localization	localization	NN	I-NP
O	1079	1081	of	of	IN	B-PP
O	1082	1085	Sp1	Sp1	NN	B-NP
O	1085	1086	,	,	,	O
O	1087	1092	which	which	WDT	B-NP
O	1093	1096	was	be	VBD	B-VP
O	1097	1104	blocked	block	VBN	I-VP
O	1105	1107	by	by	IN	B-PP
O	1108	1111	ERK	ERK	NN	B-NP
O	1112	1122	inhibition	inhibition	NN	I-NP
O	1122	1123	.	.	.	O

O	1124	1131	Finally	Finally	RB	B-ADVP
O	1131	1132	,	,	,	O
O	1133	1141	mutating	mutate	VBG	B-VP
O	1142	1145	the	the	DT	B-NP
O	1146	1149	Sp1	Sp1	NN	I-NP
O	1150	1157	binding	binding	NN	I-NP
O	1158	1163	sites	site	NNS	I-NP
O	1164	1170	within	within	IN	B-PP
O	1171	1174	the	the	DT	B-NP
O	1175	1179	VEGF	VEGF	NN	I-NP
O	1180	1188	promoter	promoter	NN	I-NP
O	1189	1191	or	or	CC	O
O	1192	1202	inhibiting	inhibit	VBG	B-NP
O	1203	1206	ERK	ERK	NN	I-NP
O	1207	1216	decreased	decrease	VBD	B-VP
O	1217	1221	VEGF	VEGF	NN	B-NP
O	1222	1230	promoter	promoter	NN	I-NP
O	1231	1239	activity	activity	NN	I-NP
O	1240	1242	in	in	IN	B-PP
O	1243	1244	M	M	NN	B-NP
O	1244	1245	-	-	HYPH	B-NP
O	1245	1248	CSF	CSF	NN	I-NP
O	1248	1249	-	-	HYPH	O
O	1249	1256	treated	treat	VBN	B-NP
O	1257	1262	human	human	JJ	I-NP
B-Cell	1263	1272	monocytes	monocyte	NNS	I-NP
O	1272	1273	.	.	.	O

O	1274	1276	To	To	TO	B-VP
O	1277	1285	evaluate	evaluate	VB	I-VP
O	1286	1289	the	the	DT	B-NP
O	1290	1300	biological	biological	JJ	I-NP
O	1301	1313	significance	significance	NN	I-NP
O	1314	1316	of	of	IN	B-PP
O	1317	1318	M	M	NN	B-NP
O	1318	1319	-	-	HYPH	B-NP
O	1319	1322	CSF	CSF	NN	I-NP
O	1323	1330	induced	induce	VBN	I-NP
O	1331	1335	VEGF	VEGF	NN	I-NP
O	1336	1346	production	production	NN	I-NP
O	1346	1347	,	,	,	O
O	1348	1350	we	we	PRP	B-NP
O	1351	1355	used	use	VBD	B-VP
O	1356	1358	an	an	DT	B-NP
O	1359	1361	in	in	FW	I-NP
O	1362	1366	vivo	vivo	FW	I-NP
O	1367	1379	angiogenesis	angiogenesis	NN	I-NP
O	1380	1385	model	model	NN	I-NP
O	1386	1388	to	to	TO	B-VP
O	1389	1399	illustrate	illustrate	VB	I-VP
O	1400	1403	the	the	DT	B-NP
O	1404	1411	ability	ability	NN	I-NP
O	1412	1414	of	of	IN	B-PP
O	1415	1416	M	M	NN	B-NP
O	1416	1417	-	-	HYPH	B-NP
O	1417	1420	CSF	CSF	NN	I-NP
O	1421	1423	to	to	TO	B-VP
O	1424	1431	recruit	recruit	VB	I-VP
B-Cell	1432	1443	mononuclear	mononuclear	JJ	B-NP
I-Cell	1444	1454	phagocytes	phagocyte	NNS	I-NP
O	1454	1455	,	,	,	O
O	1456	1464	increase	increase	VB	B-VP
O	1465	1469	VEGF	VEGF	NN	B-NP
O	1470	1476	levels	level	NNS	I-NP
O	1476	1477	,	,	,	O
O	1478	1481	and	and	CC	O
O	1482	1489	enhance	enhance	VBP	B-VP
O	1490	1502	angiogenesis	angiogenesis	NN	B-NP
O	1502	1503	.	.	.	O

O	1504	1515	Importantly	Importantly	RB	B-ADVP
O	1515	1516	,	,	,	O
O	1517	1520	the	the	DT	B-NP
O	1521	1529	addition	addition	NN	I-NP
O	1530	1532	of	of	IN	B-PP
O	1533	1534	a	a	DT	B-NP
O	1535	1547	neutralizing	neutralize	VBG	I-NP
O	1548	1552	VEGF	VEGF	NN	I-NP
O	1553	1561	antibody	antibody	NN	I-NP
O	1562	1571	abolished	abolish	VBD	B-VP
O	1572	1573	M	M	NN	B-NP
O	1573	1574	-	-	HYPH	B-NP
O	1574	1577	CSF	CSF	NN	I-NP
O	1577	1578	-	-	HYPH	B-NP
O	1578	1585	induced	induce	VBN	I-NP
B-Multi-tissue_structure	1586	1591	blood	blood	NN	I-NP
I-Multi-tissue_structure	1592	1598	vessel	vessel	NN	I-NP
O	1599	1608	formation	formation	NN	I-NP
O	1608	1609	.	.	.	O

O	1610	1620	CONCLUSION	CONCLUSION	NN	B-NP
O	1620	1621	:	:	:	O
O	1622	1627	These	These	DT	B-NP
O	1628	1632	data	datum	NNS	I-NP
O	1633	1642	delineate	delineate	VBP	B-VP
O	1643	1645	an	an	DT	B-NP
O	1646	1649	ERK	ERK	NN	I-NP
O	1649	1650	-	-	HYPH	B-ADJP
O	1651	1654	and	and	CC	O
O	1655	1658	Sp1	Sp1	NN	B-NP
O	1658	1659	-	-	HYPH	B-NP
O	1659	1668	dependent	dependent	JJ	I-NP
O	1669	1678	mechanism	mechanism	NN	I-NP
O	1679	1681	of	of	IN	B-PP
O	1682	1683	M	M	NN	B-NP
O	1683	1684	-	-	HYPH	B-NP
O	1684	1687	CSF	CSF	NN	I-NP
O	1688	1695	induced	induce	VBN	B-NP
O	1696	1700	VEGF	VEGF	NN	I-NP
O	1701	1711	production	production	NN	I-NP
O	1712	1715	and	and	CC	O
O	1716	1727	demonstrate	demonstrate	VBP	B-VP
O	1728	1731	for	for	IN	B-PP
O	1732	1735	the	the	DT	B-NP
O	1736	1741	first	first	JJ	I-NP
O	1742	1746	time	time	NN	I-NP
O	1747	1750	the	the	DT	B-NP
O	1751	1758	ability	ability	NN	I-NP
O	1759	1761	of	of	IN	B-PP
O	1762	1763	M	M	NN	B-NP
O	1763	1764	-	-	HYPH	B-NP
O	1764	1767	CSF	CSF	NN	I-NP
O	1768	1770	to	to	TO	B-VP
O	1771	1777	induce	induce	VB	I-VP
O	1778	1790	angiogenesis	angiogenesis	NN	B-NP
O	1791	1794	via	via	IN	B-PP
O	1795	1799	VEGF	VEGF	NN	B-NP
O	1800	1802	in	in	FW	B-ADVP
O	1803	1807	vivo	vivo	FW	I-ADVP
O	1807	1808	.	.	.	O

